Balanced news tone
News Sentiment
BOLT sentiment intelligence
Bolt Biotherapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
48
Balanced news tone
40 relevant articles
Price is moving more forcefully than the current news tone suggests.
74/100 classification confidence.
directly relevant articles
high-authority source matches
+16.9% over one week, +10.8% over four weeks, trend inactive, and below fair value.
BOLT Forecast — Price Target — Prediction for 2027
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Earnings
74/100 classification
One-week reaction
16.9%
Price confirming higher
Trend fit
Trend inactive
10.8% over four weeks
Fair value
-63.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
23
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
BOLT Forecast — Price Target — Prediction for 2027
Bolt Biotherapeutics, Inc. (BOLT) has a current stock price of $4.28, having increased by 1.79% in the past 24 hours. Analysts provide a wide forecast range for BOLT, with a maximum estimate of $75.00 and a minimum of $7.00. The company's stock has experienced a significant decre
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 26 Jun 2026 20:10
- Source
- TradingView
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis
Bolt Biotherapeutics Inc (BOLT) has a weak financial status with a current financial score of 5.62, ranking low within the Biotechnology & Medical Research industry. The company's operating efficiency is low, demonstrated by a significant year-over-year revenue decrease of 97.87%
- Tone
- Negative 20/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:10
- Source
- TradingKey
TradingView
Direct company coverage
A419U9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Bolt Biotherapeutics, Inc. (A419U9) stock, including analyst price targets and ratings. It also details the company's financial performance, such as recent earnings and revenue, upcoming earnings dates, and employee count. The article notes th
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 26 Jun 2026 14:40
- Source
- TradingView
TradingView
Direct company coverage
Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0)
This article provides financial actuals and estimates for Bolt Biotherapeutics, Inc. (MUN:6LP0), including analyst forecasts for its stock price, upcoming earnings reports, and past financial performance. It highlights key metrics like earnings per share, revenue, net income, EBI
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 21:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT
This article provides financial information for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), specifically focusing on its enterprise value to revenue forward. The content appears to be a stub or a placeholder page from TradingView, indicating where more detailed financial metrics f
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 19:40
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT
The article discusses the "Price to book forward" metric for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) as presented on TradingView. It specifies that this financial data point is for the BOLT Nasdaq Stock Market, with the market currently closed and no trades. The article is prim
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 19:12
- Source
- TradingView
TradingView
Direct company coverage
6LP0 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Bolt Biotherapeutics, Inc. (6LP0) stock. It includes analyst opinions on future prices, past earnings, revenue, net income, and confirms that the company does not pay dividends. The report also details the company's employee c
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 02:42
- Source
- TradingView
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Bolt Biotherapeutics Inc (BOLT), detailing analyst ratings, price targets, and revenue expectations. The company currently holds an earnings forecast score of 7.00 within the Biotechnology & Medical Research industry, with an average
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 17:39
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey examines Bolt Biotherapeutics Inc. (BOLT)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The stock closed at $4.030, down 4.28%.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 17:17
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Bolt Biotherapeutics Inc (BOLT)'s shareholder structure, detailing its major shareholders and institutional holdings. It lists key shareholders like Sofinnova Investments, Inc. and Vivo Capital, LLC, categorizes shareholders by type, and prese
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 17:17
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Bolt Biotherapeutics Inc (BOLT), detailing its current price momentum score, support and resistance levels, and technical indicator readings. It shows that BOLT has a price momentum score of 6.62 and is trading between a resistance of
- Tone
- Negative 12/100
- Event
- Market update
- Published
- 18 Jun 2026 16:39
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Bolt Biotherapeutics Inc's (BOLT) dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists a significant stock split event described as a 20-for-1 merger
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 16:17
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Bolt Biotherapeutics Inc (BOLT), categorizing it within the Biotechnology & Medical Research industry. It details the company's current risk assessment score, beta value, and various volatility and liquidity metrics. The analysis indica
- Tone
- Negative 40/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 09:12
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence
Bolt Biotherapeutics Inc (BOLT) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.88%, which is a quarter-over-quarter decrease of 51.40%. James Sim
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 18 Jun 2026 05:12
- Source
- TradingKey
TradingKey
Direct company coverage
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis
Bolt Biotherapeutics Inc (BOLT) has a current valuation score of 9.01, placing it 67th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.26, reflecting a significant drop from its recent high but an increase from its recen
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 00:12
- Source
- TradingKey
Stock Titan
Direct company coverage
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike
Bolt Biotherapeutics director Nicole Onetto was granted 5,000 stock options with an exercise price of $4.43 per share. These options are a compensation-related grant, not an open-market purchase, and will vest on the earlier of June 9, 2027, or the day before the next annual stoc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 01:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price
Bolt Biotherapeutics director Laura Berner was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholders' meeting, subject to continuous ser
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant
Bolt Biotherapeutics director Jakob Dupont was granted a stock option for 5,000 shares of common stock with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price
Bolt Biotherapeutics director Brian O’Callaghan was granted 5,000 stock options with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting, provided continuous se
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares
Bolt Biotherapeutics (NASDAQ: BOLT) director Kathleen LaPorte was granted stock options for 5,000 shares with an exercise price of $4.43 per share, expiring on June 9, 2036. The options will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meetin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:39
- Source
- Stock Titan
Finviz
Direct company coverage
BOLT - Bolt Biotherapeutics Inc Stock Price and Quote
This article provides detailed financial data and news for Bolt Biotherapeutics Inc. (BOLT), including its stock price, key financial metrics, insider transactions, and a chronological list of company news and analyst ratings. The company is a clinical-stage biopharmaceutical fir
- Tone
- Negative 40/100
- Event
- Analyst action
- Published
- 02 Jun 2026 10:10
- Source
- Finviz
Moomoo
Direct company coverage
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw
Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT), assigning a "Buy" rating and setting a price target of $22.00 per share. This target suggests a potential upside of 1150% from the stock's previous closing price.
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 29 May 2026 19:39
- Source
- Moomoo
Investing.com India
Direct company coverage
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com
Rodman & Renshaw initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a buy rating and a $22.00 price target. The firm cited the company's Claudin 18.2 immune-stimulating antibody conjugate platform and a near-term clinical readout for BDC-4182 expected in Q3 2026 as key
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 29 May 2026 08:39
- Source
- Investing.com India
Investing.com
Direct company coverage
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating
Rodman & Renshaw has initiated coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a "buy" rating and a price target of $22.00, citing the company's Claudin 18.2 immune-stimulating antibody conjugate platform. The firm anticipates a near-term clinical readout for BDC-4182 in the
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 28 May 2026 21:10
- Source
- Investing.com
MSN
Direct company coverage
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates
Bolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 m
- Tone
- Negative 25/100
- Event
- Earnings
- Published
- 21 May 2026 03:40
- Source
- MSN
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
The Manila Times
Direct company coverage
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Bolt Biotherapeutics announced its first quarter 2026 financial results, highlighting that its cash balance of $23.9 million is expected to fund operations into 2027. The company is progressing with its BDC-4182 Phase 1/2 study for gastric and gastroesophageal cancer, with initia
- Tone
- Positive 60/100
- Event
- Earnings
- Published
- 13 May 2026 13:09
- Source
- The Manila Times